Table 3

Changes from baseline in ACR core domains at week 16

ACR domainInfliximab plus methotrexate (n=56)Methotrexate (n=54)p Value
Swollen joint count, median change*–11.0–9.00.0016
Tender joint count, median change*–14.0–9.50.0007
Subject's pain assessment, mean change±SD (mm)–45.8±26.4–23.1±20.0<0.0001
Subject's GAD, mean change±SD (mm)–43.0±24.2–24.1±22.7<0.0001
Evaluator's GAD, mean change±SD (mm)–47.4±18.3–30.6±21.6<0.0001
HAQ–DI, mean change±SD–0.99±0.72–0.56±0.720.0041
CRP, median change (mg/l)–12.0–5.80.0026
ESR, median change (s)–12.0–8.00.0023
  • * Based on raw data.

  • Using VAS.

  • ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GAD, global assessment of disease activity; HAQ–DI, health assessment questionnaire–disability index.